New information from a pharmacokinetic study in patients with moderate hepatic impairment associated with significant liver tumor burden has been provided in the revised prescribing information, and other recommendations are included in the WARNINGS and DOSAGE AND ADMINISTRATION sections.Epoetin alfa - Early Communication about an Ongoing Safety Review(posted 9/23/2008)FDA has been made aware of p